Ultragenyx Pharmaceutical, based in Novato, California, focuses on developing therapies for rare genetic diseases and has four approved products, including Crysvita and Mepsevii. The company went public on January 31, 2014, and employs 1,276 people.
RARE has been in the news recently: Ultragenyx Pharmaceutical Inc. is the subject of a securities fraud class action covering purchases of its RARE stock between August 3, 2023 and December 26, 2025. Investors who bought RARE during that period and suffered losses after a stock decline of more than 25% have until April 6, 2026 to seek appointment as lead plaintiff.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.